ZIOPHARM Oncology (NASDAQ:ZIOP) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.34), Fidelity Earnings reports.
Shares of ZIOPHARM Oncology stock traded up $0.17 during mid-day trading on Friday, reaching $4.44. 1,347,500 shares of the stock were exchanged, compared to its average volume of 1,725,203. The firm has a 50-day simple moving average of $4.22 and a 200 day simple moving average of $4.88. ZIOPHARM Oncology has a fifty-two week low of $1.56 and a fifty-two week high of $7.25. The company has a market cap of $794.72 million, a price-to-earnings ratio of -9.25 and a beta of 2.60. The company has a current ratio of 6.33, a quick ratio of 6.33 and a debt-to-equity ratio of 0.01.
A number of equities research analysts recently issued reports on the stock. Raymond James set a $6.50 target price on shares of ZIOPHARM Oncology and gave the stock an “outperform” rating in a research report on Friday. BidaskClub upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, October 29th. ValuEngine cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 2nd. HC Wainwright reiterated a “buy” rating and set a $6.50 target price on shares of ZIOPHARM Oncology in a research report on Wednesday, October 2nd. Finally, Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, October 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $6.25.
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Recommended Story: What is Green Investing?
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.